Rahul Banerjee
Overview
Explore the profile of Rahul Banerjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
306
Citations
3748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, et al.
Blood Adv
. 2025 Mar;
PMID: 40088469
No abstract available.
2.
Koner K, Das K, Paitandi R, Mahapatra R, Sarkar A, Sury A, et al.
J Am Chem Soc
. 2025 Mar;
PMID: 40063599
Two-dimensional organic materials are mainly constructed by using orthogonal anisotropic connectivity of covalent bonding and π-π stacking. The noncovalent connectivity between building blocks is presumed to be too delicate to...
3.
Mahato A, Paul S, Banerjee R
Chem Soc Rev
. 2025 Mar;
PMID: 40042582
Thin film technology has emerged as a pivotal field with numerous industrial applications. Depending on their properties-such as magnetic characteristics, conductivity, architectural structure, stability, and functional backbones-thin films are widely...
4.
Indorf A, Kwok M, Jao M, Chen A, Baek G, Banerjee R, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 40016020
Background: The oncology healthcare landscape has transformed and has demonstrated the need for efficient care delivery models due to improved survival resulting in larger patient panels. Pharmacists can prescribe oral...
5.
Banerjee R, Fritz A, Akhtar O, Freeman C, Cowan A, Shah N, et al.
Leukemia
. 2025 Feb;
PMID: 39994463
No abstract available.
6.
Goel U, Zanwar S, Cowan A, Banerjee R, Khouri J, Dima D
Cancer Manag Res
. 2025 Feb;
17:357-372.
PMID: 39990276
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are two chimeric antigen receptor T cell (CAR T) therapies approved for use in patients with relapsed/refractory multiple myeloma (MM). Initially approved for...
7.
Costa L, Banerjee R, Mian H, Weisel K, Bal S, Derman B, et al.
Leukemia
. 2025 Jan;
39(3):543-554.
PMID: 39870767
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are...
8.
Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
Cicero K, Banerjee R, Kwok M, Dima D, Portuguese A, Chen D, et al.
Diagnostics (Basel)
. 2025 Jan;
15(2.
PMID: 39857099
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone...
9.
Portuguese A, Banerjee R, Chen G, Reddi S, Cowan A
JCO Oncol Pract
. 2025 Jan;
OP2400752.
PMID: 39772633
Multiple myeloma (MM), the second most common hematologic malignancy in the United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line...
10.
Olivieri D, Banerjee R
JCO Oncol Pract
. 2024 Dec;
:OP2400921.
PMID: 39705656
No abstract available.